Literature DB >> 10889370

Accuracy of the extent of axillary nodal positivity related to primary tumor size, number of involved nodes, and number of nodes examined.

R V Iyer1, A Hanlon, B Fowble, G Freedman, N Nicolaou, P Anderson, J Hoffman, E Sigurdson, M Boraas, M Torosian.   

Abstract

PURPOSE: While a number of studies have evaluated the minimum number of axillary nodes that need to be examined to accurately determine nodal positivity or negativity, there is little information on the number of nodes which must be examined to determine the extent of nodal positivity. This study attempts to determine for patients with 1-3 positive nodes the probability that the number of positive nodes reported is the true number of positive nodes as well as the probability that 4 or more nodes could be positive based on primary tumor size and number of nodes examined.
MATERIALS AND METHODS: From 1979 to 1998, 1652 women with Stages I-II invasive breast cancer underwent an axillary dissection as part of their breast conservation therapy and had more than 10 lymph nodes examined. The mean and median number of nodes identified in the dissection was 19 and 17 (range, 11-75). The median age was 55 years. A total of 1155 women had T1 tumors and 497 had T2 tumors. Of the 459 node-positive women, 72% had 1-3 positive nodes, 18% had 4-9 positive nodes, and 10% had 10 or more positive nodes. A mathematical model based on tumor size and number of nodes examined was created using the hypergeometric distribution and Bayes Theorem. The resulting model was used to estimate the accuracy of the reported number of positive nodes and the probability of 4 or more positive nodes based on various observed sampling combinations.
RESULTS: For patients with T1 tumors and 1, 2, or 3 positive nodes, the minimum number of nodes examined needed for a 90% probability of accuracy is 19, 20, and 20. For T2 tumors and 1, 2, or 3 positive nodes, a minimum of 20 nodes is required. The probability of 4 or more positive nodes increases as tumor size and the number of reported positive nodes increase and as the number of examined nodes decreases. For a 10% or less probability of 4 or more positive nodes, a patient with a T1 tumor and 1, 2, or 3 observed positive nodes would require a minimum of 8, 15, and 20 nodes removed. For a T2 tumor and 1, 2, or 3 observed positive nodes, the corresponding numbers are 10, 16, and 20.
CONCLUSION: The accuracy of the extent of axillary nodal positivity is influenced by the number of observed positive nodes, tumor size, and the number of nodes examined. Underestimation of the number of positive nodes will result in errors in the assessment of an individual's risk for locoregional recurrence, distant disease, and breast cancer death and will adversely impact on treatment recommendations. This model provides the clinician with a means for assessing the accuracy of the number of positive nodes reported in patients with 1-3 positive nodes.

Entities:  

Mesh:

Year:  2000        PMID: 10889370     DOI: 10.1016/s0360-3016(00)00574-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

1.  Statistical kinematics of axillary nodal metastases in breast carcinoma.

Authors:  Wayne S Kendal
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

2.  Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough?

Authors:  Ding Ding; Ammar A Javed; Chunhui Yuan; Michael J Wright; Zunaira N Javed; Jonathan A Teinor; I Chae Ye; Richard A Burkhart; John L Cameron; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  J Gastrointest Surg       Date:  2020-02-05       Impact factor: 3.452

3.  How do I deal with the axilla in patients with a positive sentinel lymph node?

Authors:  Conrad B Falkson
Journal:  Curr Treat Options Oncol       Date:  2011-12

4.  Lymph node ratio may be supplementary to TNM nodal classification in node-positive breast carcinoma based on the results of 2,151 patients.

Authors:  Nüvit Duraker; Bakir Bati; Zeynep Civelek Çaynak; Davut Demir
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

5.  The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer.

Authors:  Timothy A Masterson; Fernando J Bianco; Andrew J Vickers; Christopher J DiBlasio; Paul A Fearn; Farhang Rabbani; James A Eastham; Peter T Scardino
Journal:  J Urol       Date:  2006-04       Impact factor: 7.450

6.  Prognostic Significance of the Number of Removed and Metastatic Lymph Nodes and Lymph Node Ratio in Breast Carcinoma Patients with 1-3 Axillary Lymph Node(s) Metastasis.

Authors:  Nüvit Duraker; Bakır Batı; Davut Demir; Zeynep Civelek Caynak
Journal:  ISRN Oncol       Date:  2011-10-12

7.  Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy.

Authors:  Jin-Luan Li; Xiao-Yi Lin; Li-Juan Zhuang; Jun-Yan He; Qing-Qin Peng; Ya-Ping Dong; Jun-Xin Wu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

8.  A Radiation Oncologist's Guide to Axillary Management in Breast Cancer: A Walk Through the Trials.

Authors:  Julie K Jang; Elana R Sverdlik; Naomi R Schechter
Journal:  Curr Breast Cancer Rep       Date:  2019-09-14

9.  Lymph Node Ratio (LNR): Predicting Prognosis after Neoadjuvant Chemotherapy (NAC) in Breast Cancer Patients.

Authors:  Atilla Soran; Tolga Ozmen; Arsalan Salamat; Gürsel Soybir; Ronald Johnson
Journal:  Eur J Breast Health       Date:  2019-10-01

10.  Skin invasion and prognosis in node negative breast cancer: a retrospective study.

Authors:  Keiichiro Tada; Hidetomo Morizono; Kotaro Iijima; Yumi Miyagi; Seiichiro Nishimura; Masujiro Makita; Rie Horii; Futoshi Akiyama; Takuji Iwase
Journal:  World J Surg Oncol       Date:  2008-01-30       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.